Trilogy Capital’s Novartis NVS Stock Holding History

Trilogy Capital’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-45	Closed	-$3K	–	427
2018 Q3	$3K	Buy	+45	New	+$3.33K	﹤0.01%	461

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Trilogy Capital's NVS Position: Q4 2018 in Review

Trilogy Capital sold out of Novartis (NVS) in Q4 2018, closing a stake of 45 shares — an estimated $3K sold.

Trilogy Capital first reported a position in NVS in Q3 2018 and held it in 1 quarter. The position peaked at $3K in Q3 2018. 1,087 funds tracked by Wall St. Rank hold NVS as of Q4 2018.

Trilogy Capital reported no remaining Novartis position as of Q4 2018 after selling out during the quarter.
Trilogy Capital sold 45 Novartis shares in Q4 2018, an estimated $3K.
Trilogy Capital first reported a position in Novartis in Q3 2018 and held it in 1 quarter.
Trilogy Capital's Novartis position peaked at $3K in Q3 2018.
1,087 funds tracked by Wall St. Rank held Novartis as of Q4 2018.

Based on Trilogy Capital's 13F filing for Q4 2018, filed 15 Jan 2019.